2021 Q1 Form 10-Q Financial Statement
#000135657621000045 Filed on May 07, 2021
Income Statement
Concept | 2021 Q1 | 2020 Q4 | 2020 Q1 |
---|---|---|---|
Revenue | $130.9M | $143.6M | $94.98M |
YoY Change | 37.86% | 42.96% | 11.12% |
Cost Of Revenue | $14.95M | $18.50M | $4.152M |
YoY Change | 260.16% | 351.22% | 12.7% |
Gross Profit | $116.0M | $125.0M | $90.82M |
YoY Change | 27.7% | 29.8% | 11.05% |
Gross Profit Margin | 88.58% | 87.05% | 95.63% |
Selling, General & Admin | $61.46M | $56.20M | $41.61M |
YoY Change | 47.68% | 57.42% | 1.58% |
% of Gross Profit | 52.99% | 44.96% | 45.82% |
Research & Development | $34.28M | $17.90M | $18.94M |
YoY Change | 81.02% | -9.6% | 23.02% |
% of Gross Profit | 29.56% | 14.32% | 20.85% |
Depreciation & Amortization | $6.592M | $5.500M | $1.732M |
YoY Change | 280.6% | 223.53% | 3.16% |
% of Gross Profit | 5.68% | 4.4% | 1.91% |
Operating Expenses | $95.74M | $82.00M | $60.55M |
YoY Change | 58.11% | 47.75% | 7.43% |
Operating Profit | $13.21M | $43.00M | $29.01M |
YoY Change | -54.45% | 5.35% | 14.09% |
Interest Expense | $6.097M | $700.0K | $5.755M |
YoY Change | 5.94% | -121.21% | |
% of Operating Profit | 46.14% | 1.63% | 19.84% |
Other Income/Expense, Net | -$2.285M | -$4.000M | $22.00K |
YoY Change | -10486.36% | -217.65% | -101.85% |
Pretax Income | $10.93M | $39.70M | $29.03M |
YoY Change | -62.36% | -2.93% | 19.78% |
Income Tax | $5.235M | $8.900M | $7.516M |
% Of Pretax Income | 47.9% | 22.42% | 25.89% |
Net Earnings | $5.694M | $30.80M | $21.52M |
YoY Change | -73.54% | -7.03% | 17.33% |
Net Earnings / Revenue | 4.35% | 21.45% | 22.66% |
Basic Earnings Per Share | $0.11 | $0.41 | |
Diluted Earnings Per Share | $0.11 | $572.5K | $0.40 |
COMMON SHARES | |||
Basic Shares Outstanding | 52.93M shares | 52.69M shares | 52.53M shares |
Diluted Shares Outstanding | 54.20M shares | 53.58M shares |
Balance Sheet
Concept | 2021 Q1 | 2020 Q4 | 2020 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $391.1M | $422.5M | $400.9M |
YoY Change | -2.44% | 21.72% | 36.87% |
Cash & Equivalents | $255.6M | $288.6M | $225.8M |
Short-Term Investments | $135.5M | $133.9M | $175.1M |
Other Short-Term Assets | $17.60M | $18.70M | $12.60M |
YoY Change | 39.68% | 61.21% | -38.83% |
Inventory | $50.23M | $48.33M | $24.42M |
Prepaid Expenses | |||
Receivables | $127.1M | $140.9M | $119.2M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $586.0M | $630.4M | $557.0M |
YoY Change | 5.2% | 33.38% | 32.63% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $37.95M | $37.82M | $18.01M |
YoY Change | 110.7% | 121.61% | -25.88% |
Goodwill | $77.91M | $77.91M | |
YoY Change | |||
Intangibles | $358.7M | $364.3M | $23.58M |
YoY Change | 1421.42% | 1366.76% | |
Long-Term Investments | $416.6M | $350.4M | $534.7M |
YoY Change | -22.09% | -40.79% | 2.32% |
Other Assets | $30.26M | $43.25M | $538.0K |
YoY Change | 5523.98% | 97.54% | -98.12% |
Total Long-Term Assets | $921.4M | $873.7M | $632.8M |
YoY Change | 45.61% | 27.06% | 4.53% |
TOTAL ASSETS | |||
Total Short-Term Assets | $586.0M | $630.4M | $557.0M |
Total Long-Term Assets | $921.4M | $873.7M | $632.8M |
Total Assets | $1.507B | $1.504B | $1.190B |
YoY Change | 26.69% | 29.63% | 16.04% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $5.954M | $6.147M | $3.124M |
YoY Change | 90.59% | -39.38% | -56.61% |
Accrued Expenses | $70.10M | $78.93M | $152.5M |
YoY Change | -54.03% | 58.78% | 22.2% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $4.700M | ||
YoY Change | |||
Total Short-Term Liabilities | $240.8M | $245.1M | $168.3M |
YoY Change | 43.06% | 52.63% | 10.97% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $384.5M | $361.8M | $349.2M |
YoY Change | 10.11% | 4.81% | 4.77% |
Other Long-Term Liabilities | $39.68M | $42.79M | $9.743M |
YoY Change | 307.22% | 49.32% | -83.87% |
Total Long-Term Liabilities | $39.68M | $42.79M | $9.743M |
YoY Change | 307.22% | 49.32% | -97.53% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $240.8M | $245.1M | $168.3M |
Total Long-Term Liabilities | $39.68M | $42.79M | $9.743M |
Total Liabilities | $753.0M | $759.2M | $576.5M |
YoY Change | 30.62% | 34.41% | 5.7% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | $332.2M | $326.5M | $221.1M |
YoY Change | 50.27% | 63.62% | |
Common Stock | $53.00K | $53.00K | $53.00K |
YoY Change | 0.0% | 0.0% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $754.4M | $744.9M | $613.4M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $1.507B | $1.504B | $1.190B |
YoY Change | 26.69% | 29.63% | 16.04% |
Cashflow Statement
Concept | 2021 Q1 | 2020 Q4 | 2020 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | $5.694M | $30.80M | $21.52M |
YoY Change | -73.54% | -7.03% | 17.33% |
Depreciation, Depletion And Amortization | $6.592M | $5.500M | $1.732M |
YoY Change | 280.6% | 223.53% | 3.16% |
Cash From Operating Activities | $36.20M | $31.90M | $8.916M |
YoY Change | 306.01% | -27.17% | -72.98% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $1.508M | -$200.0K | $2.537M |
YoY Change | -40.56% | -90.0% | 1047.96% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$69.90M | $49.50M | $38.00M |
YoY Change | -283.95% | 130.23% | -136.89% |
Cash From Investing Activities | -$71.45M | $49.30M | $35.44M |
YoY Change | -301.61% | 152.82% | -134.32% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $2.247M | $32.00K | |
YoY Change | 6921.88% | -95.91% | |
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | $2.247M | 3.100M | $32.00K |
YoY Change | 6921.88% | 158.33% | -95.91% |
NET CHANGE | |||
Cash From Operating Activities | $36.20M | 31.90M | $8.916M |
Cash From Investing Activities | -$71.45M | 49.30M | $35.44M |
Cash From Financing Activities | $2.247M | 3.100M | $32.00K |
Net Change In Cash | -$33.00M | 84.30M | $44.39M |
YoY Change | -174.34% | 30.7% | -163.89% |
FREE CASH FLOW | |||
Cash From Operating Activities | $36.20M | $31.90M | $8.916M |
Capital Expenditures | $1.508M | -$200.0K | $2.537M |
Free Cash Flow | $34.69M | $32.10M | $6.379M |
YoY Change | 443.85% | -29.91% | -80.54% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2021Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001356576 | |
CY2021Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2021Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2021Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | |
CY2021Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
CY2021Q1 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PropertyPlantAndEquipmentNet | |
CY2021Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
14954000 | USD |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
288640000 | USD |
CY2021Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
20-2590184 | |
CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PropertyPlantAndEquipmentNet | |
CY2020Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2021Q1 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent | |
CY2021Q1 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
CY2020Q4 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OperatingLeaseLiabilityNoncurrent | |
CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OperatingLeaseLiabilityNoncurrent | |
CY2021Q1 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesNoncurrent | |
CY2020Q4 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesNoncurrent | |
CY2021Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2021Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2021Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-03-31 | |
CY2021Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2021Q1 | dei |
Entity File Number
EntityFileNumber
|
001-35518 | |
CY2021Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
SUPERNUS PHARMACEUTICALS, INC. | |
CY2021Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2021Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
9715 Key West Avenue | |
CY2021Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Rockville | |
CY2021Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MD | |
CY2021Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
20850 | |
CY2021Q1 | dei |
City Area Code
CityAreaCode
|
301 | |
CY2021Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
838-2500 | |
CY2021Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2021Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2021Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
CY2021Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
CY2021Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2021Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2021Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.001 par value per share | |
CY2021Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
53018637 | shares |
CY2021Q1 | dei |
Trading Symbol
TradingSymbol
|
SUPN | |
CY2021Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
255642000 | USD |
CY2021Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
135459000 | USD |
CY2020Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
133893000 | USD |
CY2021Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
127065000 | USD |
CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
140877000 | USD |
CY2021Q1 | us-gaap |
Inventory Net
InventoryNet
|
50226000 | USD |
CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
48325000 | USD |
CY2021Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
17631000 | USD |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
18682000 | USD |
CY2021Q1 | us-gaap |
Assets Current
AssetsCurrent
|
586023000 | USD |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
630417000 | USD |
CY2021Q1 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
416566000 | USD |
CY2020Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
350359000 | USD |
CY2021Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
37950000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
37824000 | USD |
CY2021Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
358736000 | USD |
CY2020Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
364342000 | USD |
CY2021Q1 | us-gaap |
Goodwill
Goodwill
|
77911000 | USD |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
77911000 | USD |
CY2021Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
30257000 | USD |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
43249000 | USD |
CY2021Q1 | us-gaap |
Assets
Assets
|
1507443000 | USD |
CY2020Q4 | us-gaap |
Assets
Assets
|
1504102000 | USD |
CY2021Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
70099000 | USD |
CY2020Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
78934000 | USD |
CY2021Q1 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
128736000 | USD |
CY2020Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
126192000 | USD |
CY2021Q1 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
31520000 | USD |
CY2020Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
30900000 | USD |
CY2021Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
10457000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
9082000 | USD |
CY2021Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
240812000 | USD |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
245108000 | USD |
CY2021Q1 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
366038000 | USD |
CY2020Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
361751000 | USD |
CY2021Q1 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
46200000 | USD |
CY2020Q4 | us-gaap |
Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
|
45800000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
28532000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
28579000 | USD |
CY2021Q1 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
31742000 | USD |
CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
35215000 | USD |
CY2021Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
39675000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
42791000 | USD |
CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
752999000 | USD |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
759244000 | USD |
CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
52994137 | shares |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
52994137 | shares |
CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
53000 | USD |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
53000 | USD |
CY2021Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
415950000 | USD |
CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
409332000 | USD |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
52868482 | shares |
CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
52868482 | shares |
CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
6249000 | USD |
CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
8975000 | USD |
CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
332192000 | USD |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
326498000 | USD |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
754444000 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
744858000 | USD |
CY2021Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1507443000 | USD |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1504102000 | USD |
CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
130932000 | USD |
CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
94976000 | USD |
CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
5777000 | USD |
CY2020Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
4152000 | USD |
CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
34280000 | USD |
CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
18937000 | USD |
CY2021Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
61457000 | USD |
CY2020Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
41614000 | USD |
CY2021Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
6007000 | USD |
CY2020Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1261000 | USD |
CY2021Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
1020000 | USD |
CY2020Q1 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
0 | USD |
CY2021Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
117718000 | USD |
CY2020Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
65964000 | USD |
CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
13214000 | USD |
CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
29012000 | USD |
CY2021Q1 | us-gaap |
Interest Expense
InterestExpense
|
6097000 | USD |
CY2020Q1 | us-gaap |
Interest Expense
InterestExpense
|
5755000 | USD |
CY2021Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
3812000 | USD |
CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2285000 | USD |
CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
22000 | USD |
CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
10929000 | USD |
CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
29034000 | USD |
CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
5235000 | USD |
CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
7516000 | USD |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
5694000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
21518000 | USD |
CY2021Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.11 | |
CY2020Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.41 | |
CY2021Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.11 | |
CY2020Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.40 | |
CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52927467 | shares |
CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52534787 | shares |
CY2021Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54196971 | shares |
CY2020Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53581051 | shares |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
5694000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
21518000 | USD |
CY2021Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-2726000 | USD |
CY2020Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-7583000 | USD |
CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-2726000 | USD |
CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-7583000 | USD |
CY2021Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
2968000 | USD |
CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
13935000 | USD |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
744858000 | USD |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4371000 | USD |
CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2247000 | USD |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
5694000 | USD |
CY2021Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-2726000 | USD |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
754444000 | USD |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
595428000 | USD |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3988000 | USD |
CY2020Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
32000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
21518000 | USD |
CY2020Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-7583000 | USD |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
613383000 | USD |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
5694000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
21518000 | USD |
CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6592000 | USD |
CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1732000 | USD |
CY2021Q1 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
15000000 | USD |
CY2020Q1 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
0 | USD |
CY2021Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
4287000 | USD |
CY2020Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
4061000 | USD |
CY2021Q1 | us-gaap |
Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
|
216000 | USD |
CY2020Q1 | us-gaap |
Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
|
202000 | USD |
CY2021Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
1706000 | USD |
CY2020Q1 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
249000 | USD |
CY2021Q1 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-1020000 | USD |
CY2020Q1 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
0 | USD |
CY2021Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
1202000 | USD |
CY2020Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-790000 | USD |
CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4371000 | USD |
CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3988000 | USD |
CY2021Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-2565000 | USD |
CY2020Q1 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
538000 | USD |
CY2021Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-13805000 | USD |
CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
31823000 | USD |
CY2021Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1048000 | USD |
CY2020Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-2210000 | USD |
CY2021Q1 | supn |
Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
|
368000 | USD |
CY2020Q1 | supn |
Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
|
454000 | USD |
CY2021Q1 | supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
2544000 | USD |
CY2020Q1 | supn |
Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
|
11824000 | USD |
CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-10008000 | USD |
CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-5017000 | USD |
CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
36200000 | USD |
CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
8916000 | USD |
CY2021Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
119063000 | USD |
CY2020Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
15382000 | USD |
CY2021Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
49579000 | USD |
CY2020Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
53357000 | USD |
CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1508000 | USD |
CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2537000 | USD |
CY2021Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
453000 | USD |
CY2020Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | USD |
CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-71445000 | USD |
CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
35438000 | USD |
CY2021Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2247000 | USD |
CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
32000 | USD |
CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2247000 | USD |
CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
32000 | USD |
CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-32998000 | USD |
CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
44386000 | USD |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
288640000 | USD |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
181381000 | USD |
CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
255642000 | USD |
CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
225767000 | USD |
CY2021Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1258000 | USD |
CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1258000 | USD |
CY2021Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
301000 | USD |
CY2020Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
324000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1834000 | USD |
CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1261000 | USD |
CY2021Q1 | supn |
Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
|
1432000 | USD |
CY2020Q1 | supn |
Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
|
1715000 | USD |
CY2021Q1 | supn |
Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
|
160000 | USD |
CY2020Q1 | supn |
Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
|
708000 | USD |
CY2021Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Business Organization<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel CNS product candidates including new potential treatments for ADHD, hypomobility in PD, epilepsy, depression, and rare CNS disorders. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has a portfolio of commercial products and product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Commercial Products</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (topiramate) is the first once-daily extended release topiramate product indicated for the treatment of epilepsy in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (oxcarbazepine) is indicated as therapy for partial onset seizures in adults and children 6 years to 17 years of age and is the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in pediatric patients 6 to 17 years of age. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility or "off" episodes ("end-of-dose wearing off" and unpredictable "on-off" episodes) in patients with advanced PD. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults, and it is the only Type B toxin available on the market.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Product Candidates</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">SPN-812 (viloxazine hydrochloride) is a novel non-stimulant product candidate for the treatment of ADHD in adult patients.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">SPN-830 (Apomorphine Infusion Pump) is a late-stage drug/device combination product candidate for the continuous prevention of "off" episodes in PD.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">SPN-817 is a novel product candidate for the treatment of severe epilepsy.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">SPN-820 is a first-in-class product candidate for treatment resistant depression (TRD). It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. The Company plans to make Qelbree available in the U.S. during the second quarter of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 28, 2020, the Company entered into a Sale and Purchase Agreement with US WorldMeds Partners, LLC to acquire the CNS portfolio of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). With the acquisition, completed on June 9, 2020, the Company added three established commercial products, APOKYN, XADAGO, and MYOBLOC, and a product candidate in late-stage development, SPN-830, to its portfolio. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">USWM Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further discussion on the USWM Acquisition. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 21, 2020, the Company entered into a Development and Option Agreement (Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) in TRD. In addition to entering into the Development </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Agreement in April 2020, the Company acquired an ownership position in Navitor Inc. In March 2021, Navitor Inc. underwent a legal restructuring whereby Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor Pharmaceuticals, LLC (Navitor LLC). Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further discussion on the Navitor Development Agreement and equity investment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">COVID-19 Impact</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations, and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of March 31, 2021. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.</span></div> | |
CY2021Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the creditworthiness of customers entering into revenue arrangements, the valuation of the assets and liabilities acquired in the USWM Acquisition, and the fair values of our financial instruments, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div> | |
CY2021Q1 | us-gaap |
Advertising Expense
AdvertisingExpense
|
15300000 | USD |
CY2020Q1 | us-gaap |
Advertising Expense
AdvertisingExpense
|
11600000 | USD |
CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
130932000 | USD |
CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
94976000 | USD |
CY2021Q1 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
2200000 | USD |
CY2020Q1 | supn |
Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
|
1600000 | USD |
CY2021Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
543713000 | USD |
CY2020Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
472306000 | USD |
CY2021Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
8958000 | USD |
CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
11987000 | USD |
CY2021Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
646000 | USD |
CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
41000 | USD |
CY2021Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
552025000 | USD |
CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
484252000 | USD |
CY2021Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
135459000 | USD |
CY2021Q1 | supn |
Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
|
151713000 | USD |
CY2021Q1 | supn |
Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue
|
201619000 | USD |
CY2021Q1 | supn |
Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue
|
63234000 | USD |
CY2021Q1 | supn |
Available For Sale Securities Debt Maturities Thereafter Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue
|
0 | USD |
CY2021Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
552025000 | USD |
CY2021Q1 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
|
0 | USD |
CY2020Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
76700000 | USD |
CY2021Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
1020000 | USD |
CY2021Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
77720000 | USD |
CY2021Q1 | us-gaap |
Goodwill
Goodwill
|
77911000 | USD |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
77911000 | USD |
CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
40244000 | USD |
CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
34237000 | USD |
CY2021Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
358736000 | USD |
CY2020Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
364342000 | USD |
CY2021Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
6000000.0 | USD |
CY2020Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1300000 | USD |
CY2021Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.9063 | |
CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4371000 | USD |
CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3988000 | USD |
CY2021Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
80.9063 | |
CY2021Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
5694000 | USD |
CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
21518000 | USD |
CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52927467 | shares |
CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52534787 | shares |
CY2021Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1269504 | shares |
CY2020Q1 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1046264 | shares |
CY2021Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
54196971 | shares |
CY2020Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53581051 | shares |
CY2021Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.11 | |
CY2020Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.41 | |
CY2021Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.11 | |
CY2020Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.40 | |
CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
5235000 | USD |
CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
7516000 | USD |
CY2021Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.479 | |
CY2020Q1 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.259 | |
CY2019Q1 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P10Y | |
CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
20808000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
20231000 | USD |
CY2021Q1 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
20071000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
20874000 | USD |
CY2021Q1 | supn |
Lease Right Of Use Asset
LeaseRightOfUseAsset
|
40879000 | USD |
CY2020Q4 | supn |
Lease Right Of Use Asset
LeaseRightOfUseAsset
|
41105000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
4242000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3760000 | USD |
CY2021Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
4677000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
3761000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
28532000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
28579000 | USD |
CY2021Q1 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
18499000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
20235000 | USD |
CY2021Q1 | supn |
Lease Liability
LeaseLiability
|
55950000 | USD |
CY2020Q4 | supn |
Lease Liability
LeaseLiability
|
56335000 | USD |
CY2021Q1 | supn |
Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
|
10900000 | USD |
CY2020Q4 | supn |
Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
|
11400000 | USD |
CY2021Q1 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
25987000 | USD |
CY2020Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
22208000 | USD |
CY2021Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
9330000 | USD |
CY2020Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
8985000 | USD |
CY2021Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
14909000 | USD |
CY2020Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
17132000 | USD |
CY2021Q1 | us-gaap |
Inventory Net
InventoryNet
|
50226000 | USD |
CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
48325000 | USD |
CY2021Q1 | us-gaap |
Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
|
22747000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
|
22747000 | USD |
CY2021Q1 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
|
52621000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
|
54864000 | USD |
CY2021Q1 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
|
14671000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
|
17040000 | USD |
CY2021Q1 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
37950000 | USD |
CY2020Q4 | us-gaap |
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
|
37824000 | USD |
CY2021Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
600000 | USD |
CY2020Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
500000 | USD |
CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
13080000 | USD |
CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
16008000 | USD |
CY2021Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
10635000 | USD |
CY2020Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
13890000 | USD |
CY2021Q1 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
10281000 | USD |
CY2020Q4 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
12842000 | USD |
CY2021Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5954000 | USD |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6147000 | USD |
CY2021Q1 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
5744000 | USD |
CY2020Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
0 | USD |
CY2021Q1 | supn |
Accrued Product Costs Current
AccruedProductCostsCurrent
|
4999000 | USD |
CY2020Q4 | supn |
Accrued Product Costs Current
AccruedProductCostsCurrent
|
9587000 | USD |
CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
4524000 | USD |
CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
7730000 | USD |
CY2021Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
4242000 | USD |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3760000 | USD |
CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
10640000 | USD |
CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
8970000 | USD |
CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
70099000 | USD |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
78934000 | USD |
CY2021Q1 | supn |
Accrued Rebates
AccruedRebates
|
96638000 | USD |
CY2020Q4 | supn |
Accrued Rebates
AccruedRebates
|
96589000 | USD |
CY2021Q1 | supn |
Accrued Product Returns
AccruedProductReturns
|
32098000 | USD |
CY2020Q4 | supn |
Accrued Product Returns
AccruedProductReturns
|
29603000 | USD |
CY2021Q1 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
128736000 | USD |
CY2020Q4 | supn |
Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
|
126192000 | USD |
CY2021Q1 | supn |
Non Recourse Liability Noncurrent
NonRecourseLiabilityNoncurrent
|
11763000 | USD |
CY2020Q4 | supn |
Non Recourse Liability Noncurrent
NonRecourseLiabilityNoncurrent
|
13410000 | USD |
CY2021Q1 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
18499000 | USD |
CY2020Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
20235000 | USD |
CY2021Q1 | us-gaap |
Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
|
9413000 | USD |
CY2020Q4 | us-gaap |
Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
|
9146000 | USD |
CY2021Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
39675000 | USD |
CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
42791000 | USD |
CY2021Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
5062000 | USD |
CY2020Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
4693000 | USD |
CY2021Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
1035000 | USD |
CY2020Q1 | us-gaap |
Interest Expense Other
InterestExpenseOther
|
1062000 | USD |
CY2021Q1 | us-gaap |
Interest Expense
InterestExpense
|
6097000 | USD |
CY2020Q1 | us-gaap |
Interest Expense
InterestExpense
|
5755000 | USD |
CY2021Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
4300000 | USD |
CY2020Q1 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
4100000 | USD |
CY2014Q3 | supn |
Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
|
30000000 | USD |